These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28502100)

  • 1. HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category.
    Holzschuh MA; Czyz Z; Hauke S; Inwald EC; Polzer B; Brockhoff G
    Histopathology; 2017 Oct; 71(4):610-625. PubMed ID: 28502100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis.
    Marchiò C; Lambros MB; Gugliotta P; Di Cantogno LV; Botta C; Pasini B; Tan DS; Mackay A; Fenwick K; Tamber N; Bussolati G; Ashworth A; Reis-Filho JS; Sapino A
    J Pathol; 2009 Sep; 219(1):16-24. PubMed ID: 19670217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
    Moelans CB; de Weger RA; van Diest PJ
    Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
    Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
    J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-Equivocal HER2 Invasive Breast Carcinomas: Institutional Experience and Review of Literature.
    Griffin BB; Pincus JL; Siziopikou KP; Blanco LZ
    Arch Pathol Lab Med; 2018 Dec; 142(12):1511-1516. PubMed ID: 29595316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
    Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
    Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
    Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
    Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations.
    Chibon F; de Mascarel I; Sierankowski G; Brouste V; Bonnefoi H; Debled M; Mauriac L; MacGrogan G
    Mod Pathol; 2009 Mar; 22(3):403-9. PubMed ID: 19060846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
    Bai YF; Ren GP; Wang B; Teng LS; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.
    Gunn S; Yeh IT; Lytvak I; Tirtorahardjo B; Dzidic N; Zadeh S; Kim J; McCaskill C; Lim L; Gorre M; Mohammed M
    BMC Cancer; 2010 Jul; 10():396. PubMed ID: 20667129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
    Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of Alternate, Noncentromeric Chromosome 17 Reference Probe for Human Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Testing in Breast Cancer Cases.
    Pai T; Shet T; Patil A; Shetty O; Singh A; Desai SB
    Arch Pathol Lab Med; 2018 May; 142(5):626-633. PubMed ID: 29384691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.
    Press MF; Seoane JA; Curtis C; Quinaux E; Guzman R; Sauter G; Eiermann W; Mackey JR; Robert N; Pienkowski T; Crown J; Martin M; Valero V; Bee V; Ma Y; Villalobos I; Slamon DJ
    JAMA Oncol; 2019 Mar; 5(3):366-375. PubMed ID: 30520947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment and significance of human epidermal growth factor receptor 2 gene status in breast cancer with polysomy of chromosome 17].
    Zhang H; Si JW; Zhang S; Wang Y; Li D; Li T
    Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):124-9. PubMed ID: 26899332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
    Xu FP; Wang K; Xu J; Chen J; Zhang YF; Wu HM; Zhang MH; Long XX; Luo XL; Zhang KP; Lin DY; Liu YH
    Breast Cancer Res Treat; 2017 Dec; 166(3):757-764. PubMed ID: 28861637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
    Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
    J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.